Four new labs joining the faculty
Prof. Dr. Lichtenthaler's group study how Alzheimer’s disease develops in the brain on the molecular and cellular level. The aim of their research is to better understand the disease causes and to develop new diagnostic, therapeutic and preventive approaches. Additionally, the goal is to predict possible side effects of Alzheimer-targeted drugs and, thus, make drug development safer. Prof. Lichtenthaler is chair of Neuroproteomics at the TUM School of Medicine and Group Leader at the German Center for Neurodegenerative Diseases (DZNE).
Dr. Michalakis and his group focus on understanding disease mechanisms and developing treatments for inherited retinal diseases. In addition, the group looks into epigenetic mechanisms of gene regulation in healthy and diseased neurons. Stylianos Michalakis is a member of the Excellence Cluster "Center for Integrated Protein Science Munich" and a founding member of the RD-CURE consortium, that currently runs the first German ocular gene therapy trial.
The research aim of the Stefan Stricker lab is to investigate which of the myriad of epigenomic marks have significant functional relevance in mediating cell identity or disease phenotypes. Dr. Stefan H. Stricker is based in the Institute for Stem Cell Research at the Helmholtz Zentrum München as a guest scientist associated with LMU Munich, in his position as head of the MCN Junior Research group "Epigenome Editing" at the BioMedical Center.
Dr. Carsten Wotjak studies the role of (endo)cannabinoids in fear and anxiety by a variety of different behavioral tasks an (non)invasive methods. His research group has pioneered the establishment of mouse models of psychiatric diseases and emotional dysregulation and achieved major contributions regarding the neurobiology of the endogenous cannabinoid system in development and extinction of exaggerated fear. Dr. Wotjak is head of the Research Group "Neuronal Plasticity" at the Max Planck Institute of Psychiatry.
For more information visit our Faculty page.